ClinicalTrials.gg
TerminatedNCT03794583PERFECT OLEUpdated May 27, 2026Results posted

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

A Phase 3 interventional study of Inhaled treprostinil solution in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by United Therapeutics. Terminated at 32 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
15th of 37
41 · median 32
Started
2018
with 2 others
Phase 3
15 of 38
1 open now
Registered
30th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 3, and was the 30th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

Read the detailed description

This is a multi-center, open-label study for eligible participants who completed all scheduled study visits during the Treatment Period of Study RIN-PH-304.

Participants who provide informed consent for this open-label extension study on or prior to the final study visit of RIN-PH-304 may participate in the study, provided all other eligibility criteria are met. The RIN-PH-304 final study visit and the RIN-PH-305 Enrollment Visit will occur on the same day.

All participants will reinitiate inhaled treprostinil at 3 breathes (18 micrograms [mcg]) 4 times daily (QID) during waking hours. Study drug doses should be maximized to tolerability throughout the study, and dose titrations should occur as rapidly as possible (as directed by the Investigator) with a target dosing regimen of 15 breaths QID or the maximum tolerated dose.

03

Conditions studied

  • Pulmonary Hypertension
  • Chronic Obstructive Pulmonary Disease

Keywords

  • Treprostinil
  • Lung Diseases
  • Hypertension
  • Vascular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant voluntarily gives to participate in the study.
  2. Participant completed Study RIN-PH-304.
  3. Women of (defined as less than 1 year and not surgically sterile) must agree to practice abstinence or use 2 highly effective methods of (defined as a method of birth control that results in a low failure rate, [less than 1% per year], such as approved hormonal contraceptives, barrier methods [such as condom or diaphragm] used with a spermicide, or an intrauterine device) for the duration of study treatment and for 48 hours after discontinuing study drug.
  4. Males with a partner of childbearing potential must agree to use a barrier method (condom) with a spermicide for the duration of treatment and for at least 48 hours after discontinuing study drug.

Exclusion criteria

Exclusion Criteria:

  1. The participant is pregnant or lactating.
  2. The participant was prematurely discontinued from Study RIN-PH-304.
  3. The participant is intolerant to inhaled prostanoid therapy.
  4. The participant is unwilling or unable to use Sponsor-provided devices (actigraph, spirometer, or smart device).
  5. The participant is scheduled to receive another drug, device, or therapy during the course of this study.
  6. Any other illness or abnormal laboratory value(s) that, in the opinion of the Investigator, might adversely affect the interpretation of the study data.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Inhaled Treprostinil Solution

    Inhaled treprostinil solution (0.6 milligrams per milliliter \[mg/mL\], 6 mcg/breath) QID during waking hours.

    Drug: Inhaled treprostinil solution

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent was defined as any AE occurring/worsening at any time after a participant was exposed to study drug up until 7 days after the last dose of study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 4 years

Secondary outcomes

  1. Change From Baseline to Week 6 in 6-Minute Walk Distance (6MWD)

    6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6-minute walk test (6MWT) was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded.

    Time frame: Baseline, Week 6

  2. Change From Baseline to Week 6 in Borg Dyspnea Score

    The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.

    Time frame: Baseline, Week 6

  3. Change From Baseline to Week 6 in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)

    The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.

    Time frame: Baseline, Week 6

07

Results

Posted Dec 18, 2023
Limitations and caveats
Per sponsor decision, the study was terminated early.

Participant flow

Participant flow — Overall Study
MilestoneTreprostinil
Started41
Received at least 1 dose of study drug41
Completed0
Not completed41
Withdrew: Death8
Withdrew: Study terminated by sponsor24
Withdrew: Withdrawal by subject9

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent was defined as any AE occurring/worsening at any time after a participant was exposed to study drug up until 7 days after the last dose of study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTreprostinil
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)35
SecondaryChange From Baseline to Week 6 in 6-Minute Walk Distance (6MWD)

6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6-minute walk test (6MWT) was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded.

Time frame:
Baseline, Week 6
Reported as:
Mean · meters
Change From Baseline to Week 6 in 6-Minute Walk Distance (6MWD)
metersTreprostinil
Baseline226.5 ± 88.91
Change at Week 615 ± 43.58
SecondaryChange From Baseline to Week 6 in Borg Dyspnea Score

The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline to Week 6 in Borg Dyspnea Score
score on a scaleTreprostinil
Baseline5.03 ± 2.57
Change at Week 60.38 ± 1.94
SecondaryChange From Baseline to Week 6 in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)

The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.

Time frame:
Baseline, Week 6
Reported as:
Mean · nanogram/liter (ng/L)
Change From Baseline to Week 6 in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
nanogram/liter (ng/L)Treprostinil
Baseline1279.6 ± 2080.19
Change at Week 6-155.55 ± 558.96

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treprostinil8/41 (19.5%)13/41 (31.7%)22/41 (53.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventTreprostinil
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/41
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/41
Acute myocardial infarctionCardiac disorders2/41
Cardiac arrestCardiac disorders2/41
Sudden deathGeneral disorders2/41
COVID-19 pneumoniaInfections and infestations2/41
AnaemiaBlood and lymphatic system disorders1/41
Myocardial infarctionCardiac disorders1/41
Right ventricular failureCardiac disorders1/41
COVID-19Infections and infestations1/41
Most frequent other events
Most frequent other events
EventTreprostinil
CoughRespiratory, thoracic and mediastinal disorders8/41
HeadacheNervous system disorders6/41
COVID-19Infections and infestations5/41
Back painMusculoskeletal and connective tissue disorders4/41
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/41
DyspnoeaRespiratory, thoracic and mediastinal disorders4/41
AnxietyPsychiatric disorders3/41

Baseline characteristics

Safety population included all participants who received at least 1 dose of inhaled treprostinil.

Age, Continuous
Age, Continuous(years)Treprostinil
Mean68.24 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)Treprostinil
Female17
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treprostinil
Hispanic or Latino2
Not Hispanic or Latino39
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treprostinil
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American8
White31
More than one race2
Unknown or Not Reported0
08

Study locations

32 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • St. Francis Sleep Allergy & Lung Institute
    Clearwater, Florida 33765, United States
  • St. Vincent's Lung, Sleep, and Criticial Care Specialists
    Jacksonville, Florida 32204, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Pulmonary & Critical Care of Atlanta
    Atlanta, Georgia 30342, United States
  • Georgia Clinical Research
    Austell, Georgia 30106, United States
  • University of Illinois Medical Center
    Chicago, Illinois 60612, United States
  • St. Vincent Medical Group, Inc.
    Indianapolis, Indiana 46260, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Spectrum Health
    Grand Rapids, Michigan 49546, United States
  • Memorial Hospital at Gulfport
    Gulfport, Mississippi 39501, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • University of Rochester Medical Center
    Rochester, New York 14623, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • The Carl and Edyth Lindner Research Center at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792, United States
  • Lady Davis Carmel Medical Centre
    Haifa, 34362, Israel
  • Hadassah-Hebrew University Hospital
    Jerusalem, 9112001, Israel
  • Rabin Medical Center
    Petah Tikva, 4941492, Israel
  • "Azienda Unita Sanitaria Locale Della Romagna Ospedale ""Gian Battista Morgagni"" - Luigi Pierantoni"" di Forli"
    Forlì, Forli 47121, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Nov 2022, 47 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2019
First posted
Jan 7, 2019
StartActual
Dec 21, 2018
Primary completionActual
Nov 29, 2022
CompletionActual
Nov 29, 2022
Results first posted
Dec 18, 2023
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03794583
Responsible party
Sponsor
First posted
Jan 7, 2019
Start date
Dec 21, 2018
Primary completion
Nov 29, 2022
Completion
Nov 29, 2022
Results posted
Dec 18, 2023
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion